Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France.

Mark OppeBogdan MuresanKatie ChanXenia RaduBob G SchultzRobin S TurpinArnaud NucitElisabetta Fenu

Published in: Expert review of pharmacoeconomics & outcomes research (2023)

Introducing vedolizumab SC as MT after IV induction is expected to have substantial cost savings to a health plan from a French payer's perspective versus a world without vedolizumab SC.

Keyphrases

ulcerative colitis
rheumatoid arthritis
public health
healthcare
patients with inflammatory bowel disease
mental health
stem cells
risk assessment
human health
climate change
cell therapy